:

Marie-Therese Holzer1, Nikolas Ruffer2, Tobias B Huber3

  • 1Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany m.holzer@uke.de.

RMD open
|December 15, 2023
PubMed
概括

针对CD38的抗体达拉图马布对耐药性自身免疫性疾病有很大的前景,81%的患者经历了缓解或改善. 需要进一步的临床试验来优化其使用和管理副作用.